Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Claxton

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Pharmacoeconomics|September 5, 2008
Exploring uncertainty in cost-effectiveness analysisKarl Claxton
Health Economics|August 3, 2018
Comment: Positive tails and normative dogsKarl Claxton
Health Economics|May 31, 2007
OFT, VBP: QED?Karl Claxton
Pharmacoeconomics|December 22, 2011
Real economics needs to reflect real decisions: a response to JohnsonMark Sculpher, Karl Claxton
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 12, 2011
Addressing adoption and research design decisions simultaneously: the role of value of sample information analysisClaire McKenna, Karl Claxton
Health Economics|July 28, 2010
Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methodsMark Sculpher, Karl Claxton
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 17, 2009
Dimensions of design space: a decision-theoretic approach to optimal research designStefano Conti, Karl Claxton
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 11, 2005
Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?Mark Sculpher, Karl Claxton
Health Economics|March 26, 2011
Budget allocation and the revealed social rate of time preference for healthMike Paulden, Karl Claxton
Journal of Medical Ethics|August 1, 2007
Rights, responsibilities and NICE: a rejoinder to HarrisKarl Claxton, Anthony J Culyer
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Pharmacoeconomics|September 5, 2008
Exploring uncertainty in cost-effectiveness analysisKarl Claxton
Health Economics|August 3, 2018
Comment: Positive tails and normative dogsKarl Claxton
Health Economics|May 31, 2007
OFT, VBP: QED?Karl Claxton
Pharmacoeconomics|December 22, 2011
Real economics needs to reflect real decisions: a response to JohnsonMark Sculpher, Karl Claxton
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 12, 2011
Addressing adoption and research design decisions simultaneously: the role of value of sample information analysisClaire McKenna, Karl Claxton
Health Economics|July 28, 2010
Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methodsMark Sculpher, Karl Claxton
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 17, 2009
Dimensions of design space: a decision-theoretic approach to optimal research designStefano Conti, Karl Claxton
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 11, 2005
Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?Mark Sculpher, Karl Claxton
Health Economics|March 26, 2011
Budget allocation and the revealed social rate of time preference for healthMike Paulden, Karl Claxton
Journal of Medical Ethics|August 1, 2007
Rights, responsibilities and NICE: a rejoinder to HarrisKarl Claxton, Anthony J Culyer
Pageof 12